Servier’s EU Nightmare Continues As Commission Moves To Shut Down Disputed IP Practices

The European Commission has sent a statement of objections to Servier SA alleging that the company willfully employed a series of negative practices to prevent or discourage other manufacturers from launching competitor products to its cardiovascular therapy Coversyl (perindopril).

The move against pay-for-delay practices comes as no surprise, but it caps a miserable few years for Servier and signals...